RxDoctor Payments Data

Renea Older, APRN

Family · Circleville, OHNPI 1568937712

Payments from drug & device makers

$3,653in general payments, 2019–2025

Across 63 payments — averaging $57.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Pfizer$370
  • Myovant Sciences Inc.$224
  • Coloplast$202
  • Bluewind Medical$149
  • Bayer$142
  • plus $858 from 13 others

What the payments were for

  • Speaking & faculty fees$311%
  • Travel & lodging$1,06729%
  • Food & beverage$2,38165%
  • Education$1745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,653 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$89,003
Medicare patients
476
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron167$98,192
GemtesaVibegron49$36,247
Tamsulosin Hcl474$6,614
Oxybutynin Chloride ErOxybutynin Chloride291$5,835
Potassium Citrate ErPotassium Citrate53$5,495
Testosterone23$5,063
Dutasteride142$4,487
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst125$4,180
Finasteride381$4,049
Trospium Chloride56$3,495
Estradiol35$2,347
Testosterone Cypionate58$1,770
Solifenacin Succinate42$1,518
Alfuzosin Hcl ErAlfuzosin Hcl94$1,514
Trimethoprim22$1,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$65$98,192167 claims
Sumitomo Pharma America, Inc.Gemtesa$31$36,24749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Circleville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →